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Abstract
Background: To evaluate if early improvements in pain and function with subcuta-
neous tanezumab are meaningful and sustained over 24 weeks.
Methods: Patients with moderate- to- severe osteoarthritis (hip or knee) in Europe and 
Japan were randomized to placebo, tanezumab 2.5 mg or tanezumab 5 mg (baseline, 
Week 8 and Week 16). Outcomes included: average daily index joint pain score, Western 
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscales, rescue 
medication use, WOMAC responders (within- patient ≥30% reduction in WOMAC 
Pain or Physical Function), Outcome Measures in Rheumatology- Osteoarthritis 
Research Society International (OMERACT- OARSI) responders (within- patient) and 
Patient- reported Treatment Impact Assessment- Modified questionnaire.
Results: Patients received placebo (n  =  282), tanezumab 2.5  mg (n  =  283) or 
tanezumab 5 mg (n = 284). Changes from baseline in average daily index joint 
pain (within the first week) and WOMAC subscales (Week 2 through Week 24) 
were greater for each tanezumab group versus placebo (least squares [LS] mean, 
unadjusted p ≤ .05). Rescue medication use (days/week) was lower for each tan-
ezumab group versus placebo from Week 2 through Week 12 (LS mean, unad-
justed p ≤ .05) but not at Week 16 or 24. A higher proportion of each tanezumab 
group than placebo achieved  ≥30% reduction from baseline in WOMAC Pain 
or Physical Function, or OMERACT- OARSI response (Week 2 through Week 
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial- NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
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1 |  INTRODUCTION
Quality of life can be significantly impacted by the pain caused 
by osteoarthritis (OA) (Osteoarthritis Research Society 
International, 2016). Commonly used analgesics (acetamin-
ophen, nonsteroidal anti- inflammatory drugs [NSAIDs] 
and tramadol/other opioids) (Bannuru et  al.,  2019; Geenen 
et al., 2018; Kolasinski et al., 2020) are not adequately effec-
tive or suitable for all patients (Kolasinski et al., 2020), and 
alternative well- tolerated treatments that provide meaningful 
and timely pain relief and improved function for a prolonged 
period are needed.
Studies using intravenous administration of the nerve 
growth factor monoclonal antibody, tanezumab, showed 
early and sustained efficacy in patients with hip or knee 
OA (Brown et al., 2012, 2013; Lane et al., 2010; Spierings 
et al., 2013). A dose- titration study of subcutaneous tane-
zumab in patients in North America with hip or knee OA 
demonstrated efficacy within the first week that was gener-
ally sustained over a 16- week treatment period (Schnitzer 
et al., 2019, 2020).
In this placebo- controlled, Phase 3 study of patients in 
Europe and Japan with moderate- to- severe OA of the hip or 
knee for whom standard analgesics were inadequate or un-
suitable, tanezumab 2.5  mg administered subcutaneously 
resulted in statistically significant improvements in Western 
Ontario and McMaster Universities OA Index (WOMAC*) 
Pain and Physical Function subscales, but not patient's global 
assessment of OA (PGA- OA), at Week 24 (Berenbaum 
et al., 2020). The aim of the current exploratory analysis of 
data from this study (Berenbaum et al., 2020) was to evalu-
ate if the early pain reduction seen with subcutaneous tane-
zumab is meaningful and sustained over a 24- week treatment 
period. Subgroup analyses assessed efficacy in patients with 
the most radiographically severe OA and in the subgroup of 
patients from Japan.
*© 1996 Nicholas Bellamy. WOMAC® is a registered
trademark of Nicholas Bellamy (CDN, EU, USA).
2 |  METHODS
This double- blind, parallel- group, randomized, placebo- 
controlled Phase 3 study (ClinicalTrials.gov: NCT02709486) 
of patients enrolled in Europe or Japan comprised a screening 
period (≤37 days), a double- blind treatment period (24 weeks), 
and a safety follow- up period (24 weeks). Eligibility criteria 
included OA of the hip or knee (radiographically confirmed 
by a central reader, Kellgren- Lawrence [KL] (Kellgren & 
Lawrence, 1957) grade ≥2); WOMAC (Theiler et al., 2002) 
Pain subscale score ≥5 in the index joint (at screening and 
baseline); WOMAC Physical Function subscale score ≥5 in 
the index joint at baseline; and “fair”, “poor” or “very poor” 
PGA- OA at baseline. Patients also had a documented history 
of: (a) insufficient pain relief from acetaminophen; (b) inad-
equate pain relief from or intolerance or contraindication to 
NSAIDs; and (c) inadequate pain relief from or intolerance 
or contraindication to either tramadol or opioids (or were un-
willing to take opioids). This study was not a flare design 
(i.e., there was no requirement for patients to have increased 
pain after stopping prior analgesics during the screening 
phase). Following a washout period of prior analgesics, as-
sessments at baseline, Week 8, and Week 16 were conducted 
before administration of study medication. Patients received 
three doses of placebo, tanezumab 2.5  mg or tanezumab 
5 mg administered subcutaneously at baseline, Week 8 and 
Week 16. Except for the 24 hr prior to any study visit for 
efficacy assessments, acetaminophen (rescue therapy, up to 
4,000 mg/day or as permitted by local or national labelling) 
was allowed for OA or other types of pain or illness prior to 
randomization and up to 5 days/week through Week 24, and 
then as needed until Week 32 (Berenbaum et al., 2020). Full 
24, unadjusted p ≤ .05), or were satisfied with treatment at Week 24 (unadjusted 
p ≤ .05).
Conclusions: Subcutaneous tanezumab, compared with placebo, reduced pain within 
the first week, and pain and function were improved throughout 24 weeks. The propor-
tions of responders and patients satisfied were higher with tanezumab than placebo.
ClinicalTrials.gov:NCT02709486.
Significance: This exploratory analysis of data from a placebo- controlled, Phase 3 
study of patients with moderate- to- severe osteoarthritis of the hip or knee for whom 
standard analgesics were not effective or could not be taken, found that onset of 
efficacy of subcutaneous tanezumab was within the first week, and efficacy was 
maintained through the 24- week treatment period. Tanezumab was effective in those 
patients with the most radiologically severe osteoarthritis.
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methodology for this study has been published previously 
(Berenbaum et al., 2020).
2.1 | Assessments
Efficacy was assessed during the 24- week double- blind 
treatment period. An assessment for rebound pain (pain 
after treatment effect had subsided, indicated by wors-
ening of pain compared with baseline) was conducted at 
Week 32, which was 16 weeks after the last dose of study 
medication.
Using an electronic diary (palm- held device) each day 
from randomization, patients assessed their average daily 
index joint pain during the past 24 hr on an 11- point numeric 
rating scale, with higher score indicating worse pain. During 
the first post- randomization clinic visit at Week 2 and subse-
quent clinic visits at Weeks 4, 8, 12, 16, 24 and 32, patients 
completed the Pain, Physical Function and Stiffness subscales 
of the WOMAC questionnaire electronically, assessing index 
joint symptoms within the last 48 hr on 11- point numeric rat-
ing scales (with higher scores indicating higher levels of pain, 
worse function or more stiffness). The PGA- OA was assessed 
on a 5- point Likert scale with higher score indicating worse 
assessment. Each day to Week 24, patients electronically re-
corded any use of rescue medication, with bottles returned at 
each visit for assessment of compliance. The Patient Reported 
Treatment Impact Assessment- Modified (mPRTI) comprised 
three questions rated on 5- point Likert scales, with higher 
scores indicating greater satisfaction, preference or willing-
ness to use the study medication (at Week 16 and 24 only).
2.2 | Statistical analyses
The primary efficacy population comprised all randomized 
patients who received at least one dose of study medication.
Change from baseline in WOMAC Pain, WOMAC Physical 
Function and PGA- OA scores were prespecified coprimary 
(at Week 24) or secondary (at Weeks 2, 4, 8, 12, 16, and 32) 
endpoints. All other endpoints were prespecified secondary 
endpoints. As reported previously (Berenbaum et al., 2020), 
the coprimary endpoints and three key secondary endpoints 
(proportion of patients with ≥50% improvement in WOMAC 
Pain score at Week 24, change from baseline to Week 2 in 
WOMAC Pain score and change from baseline to Week 1 in 
average daily index joint pain score) were included in a mul-
tiple testing procedure to control the family- wise type 1 error, 
using a graphical approach of gatekeeping strategy (Bretz 
et al., 2011). The analyses of these key secondary endpoints 
were gated by the primary analysis (Berenbaum et al., 2020), 
and because the tanezumab 2.5 mg dose failed to achieve sta-
tistical significance on one coprimary endpoint (PGA- OA at 
Week 24) (Berenbaum et al., 2020), hypothesis testing of the 
three key secondary endpoints could not be performed for 
the related study objectives. However, the objective of this 
manuscript was to evaluate overall onset, maintenance, and 
responder rates, including other secondary endpoints in ad-
dition to primary and key secondary endpoints. The data in 
this manuscript are presented with unadjusted p- values, least 
squares (LS) mean or proportion of patients achieving crite-
ria (e.g., ≥30% improvement), and the corresponding 95% 
confidence interval, for all secondary endpoints. Findings 
are described as statistically significant (where p ≤ .05 in the 
framework of gatekeeping strategy) or greater/better (from an 
exploratory perspective, when point estimate, LS mean, and 
% responders were better for tanezumab than placebo and un-
adjusted p ≤ .05).
Between- group differences in least squares mean change 
from baseline in average daily index joint pain score (cal-
culated daily for Days 1 through 7, and as weekly means at 
Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24) and WOMAC 
subscales and PGA- OA (at Weeks 2, 4, 8, 12, 16 and 24) were 
tested using analysis of covariance (ANCOVA) models with 
multiple imputation for missing data dependent on the reason 
for missing data (for details, see Methods S1). Effect sizes 
(placebo- adjusted LS mean change from baseline divided by 
model- based standard deviation [SD]) were calculated post 
hoc. Between- group differences in rescue medication use 
were analysed at Weeks 2, 4, 8, 12, 16 and 24 using last ob-
servation carried forward (LOCF) and a Negative Binomial 
model. The proportions of patients achieving ≥30%, ≥50%, 
≥70% or ≥90% improvements from baseline in WOMAC 
Pain or Physical Function scores, and the proportion meet-
ing the Outcome Measures in Rheumatology- Osteoarthritis 
Research Society International (OMERACT- OARSI) (Pham 
et al., 2004) treatment response criteria, were calculated. A 
within- patient decrease in WOMAC Pain score of ≥30% 
is reported to be moderately clinically important (Dworkin 
et  al.,  2008; Farrar et  al.,  2001). OMERACT- OARSI re-
sponse is defined as within- patient improvement from base-
line of (a) ≥50% and ≥2 points in either WOMAC Pain or 
Physical Function scores, or (b) ≥20% and ≥1 point in two 
of WOMAC Pain, Physical Function, or PGA- OA scores. 
Between- group differences in these responder endpoints were 
tested using logistic regression with mixed baseline observa-
tion carried forward/LOCF, dependent on the reason for the 
missing data. Between- group differences in responses to the 
mPRTI were analysed using a Cochran- Mantel- Haenszel test.
Post hoc exploratory subgroup analyses assessed the ef-
ficacy of tanezumab in the most severe patients, based on 
KL grade of the index joint (grade 2 or 3 [KL2/3], or grade 
4 [KL4]). Prespecified exploratory analyses assessed the 
efficacy of tanezumab in the small subgroup of patients 
from Japan, using the same models as for the total popula-
tion. Subgroup analyses of the patients from Europe were 
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not conducted since they comprised the majority of the total 
population.
SAS software version 9.4 (Cary, North Carolina) was used 
for all statistical analyses.
3 |  RESULTS
3.1 | Demographics and baseline 
characteristics
The 849 patients were enrolled in Europe (87.5%, 743/849) 
and Japan (12.5%, 106/849). Of the total population (pla-
cebo, n  =  282; tanezumab 2.5  mg, n  =  283; tanezumab 
5  mg, n  =  284), 69.1% (587/849) were female, and the 
index joint was a knee in 83.0% (705/849), KL2 or KL3 in 
63.7% (541/849), and KL4 in 36.0% (306/849) of patients 
(Berenbaum et al., 2020). In the subgroup of patients from 
Japan (placebo, n  =  34; tanezumab 2.5  mg, n  =  38; tane-
zumab 5 mg, n = 34), 69.8% (74/106) were female, and the 
index joint was a knee in 88.7% (94/106), KL2 or KL3 in 
60.4% (64/106), and KL4 in 39.6% (42/106) of patients. At 
baseline, across the three treatment groups, WOMAC Pain 
scores (mean) were 6.59 to 6.70 (Berenbaum et al., 2020) in 
the total population and 6.40 to 6.74 in the subgroup from 
Japan; WOMAC Physical Function scores were 6.67 to 6.77 
(Berenbaum et al., 2020) and 6.51 to 6.80, respectively. The 
subgroup from Japan had a lower mean body mass index, 
shorter mean duration since index joint OA diagnosis, and 
fewer patients had an index joint of KL2 compared with the 
total population (Table S1). At study entry, the most frequent 
reason for treatment failure with acetaminophen, NSAIDs 
and tramadol was inadequate pain relief in both the total 
population and the subgroup from Japan; the most frequent 
reason for treatment failure with opioids was that the patient 
was unwilling to take them, and this was the only reason in 
the subgroup from Japan (Table S2).
3.2 | Early efficacy
In the total population, improvements from baseline in av-
erage daily index joint pain score (LS mean) were greater 
for each tanezumab group compared with the placebo group 
within the first week, with onset evident at Day 2 (tan-
ezumab 2.5 mg) and Day 4 (tanezumab 5 mg) (Figure 1a). 
The changes from baseline (LS mean difference [95% con-
fidence interval] vs. placebo) were −0.50 (−0.77, −0.23) for 
tanezumab 2.5 mg (unadjusted p = .0003) and −0.26 (−0.53, 
0.01) for tanezumab 5  mg (unadjusted p  =  .0638) at Day 
2, and −0.65 (−0.93, −0.37) for tanezumab 2.5 mg (unad-
justed p < .0001) and −0.48 (−0.77, −0.20) for tanezumab 
5 mg (unadjusted p = .0008) at Day 4. At the time of the first 
post- randomization clinic assessment (Week 2), LS mean 
reductions from baseline in WOMAC Pain (Berenbaum 
et  al.,  2020), Physical Function, and Stiffness subscale 
scores and PGA- OA score were greater in each tanezumab 
group compared with the placebo group (unadjusted p ≤ .05, 
Figure 2 and Table 1). Effect sizes for the tanezumab 2.5 mg 
and 5 mg groups, respectively, were 0.39 and 0.29 for aver-
age daily index joint pain at Week 1 and 0.43 and 0.22 for 
WOMAC Pain at Week 2 (Table S3).
F I G U R E  1  Change from baseline in average daily index joint pain (a) daily during the first week and (b) weekly through the 24- week 
treatment period (total population). *Unadjusted p ≤ .05 for tanezumab 2.5 mg versus placebo. +Unadjusted p ≤ .05 for tanezumab 5 mg versus 
placebo. The LS means with standard errors have been previously published for Week 1 (Berenbaum et al., 2020). Average daily index joint pain 
during the past 24 hr assessed on an 11- point numeric rating scale (0 = no pain, 10 = worst possible pain) in response to: “Select the number that 
best describes your average pain in your index joint (e.g., the right knee) in the past 24 hr.” Multiple ANCOVA models (for each timepoint in panel 
a and b) with multiple imputation for missing data, including model terms for baseline score, index joint, highest KL grade and treatment group, 
with study site as a random effect. At baseline, average daily index joint pain scores were (mean ± SD, observed data): 6.79 ± 1.56 (n = 278), 
7.03 ± 1.38 (n = 280), and 6.90 ± 1.43 (n = 280), for placebo, tanezumab 2.5 mg and tanezumab 5 mg, respectively. ANCOVA, analysis of 
covariance; CI, confidence interval; KL, Kellgren- Lawrence; LS, least squares; SD, standard deviation
Placebo (n = 282) Tanezumab 2.5 mg (n = 283) Tanezumab 5 mg (n = 284)
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Rescue medication use (number of days per week) 
was lower in the tanezumab 2.5 mg (LS mean 2.12 days, 
unadjusted p  =  .0001) and 5  mg (2.39  days, unadjusted 
p  =  .0067) groups compared with the placebo group 
(3.17  days) at Week 2 (Table  2). The amount of rescue 
medication used per week (mg) was lower in the tanezumab 
2.5 mg group (LS mean 2,283.4 mg, unadjusted p = .0441) 
but not the tanezumab 5 mg group (2,703.4 mg, unadjusted 
p = .1895) compared with the placebo group (3,690.6 mg) 
at Week 2 (Table S4).
At Week 2, a higher proportion of patients in the tane-
zumab 2.5 mg group than in the placebo group achieved ≥30% 
reduction from baseline in WOMAC Pain (46.8% [132/282] 
vs. 33.5% [94/281], unadjusted p  =  .0006, Figure  3a) or 
Physical Function (44.3% [125/282] vs. 30.2% [85/281], un-
adjusted p = .0003, Figure 4a) scores, or met the criteria for 
OMERACT- OARSI response (63.1% [178/282] vs. 44.1% 
[124/281], unadjusted p < .0001, Figure 5). The proportion 
of patients meeting the ≥50% reduction criteria at Week 2 
was higher for the tanezumab 2.5 mg group versus placebo 
F I G U R E  2  Change from baseline in (a) WOMAC Pain score, (b) WOMAC Physical Function score, (c) WOMAC Stiffness score and (d) 
PGA- OA score during the 24- week treatment period (total population). *Unadjusted p ≤ .05 for tanezumab 2.5 mg versus placebo. +Unadjusted 
p ≤ .05 for tanezumab 5 mg versus placebo. The LS means with standard errors have been previously published for change from baseline in 
WOMAC Pain at Week 2 and Week 24, and WOMAC Physical Function and PGA- OA at Week 24 (Berenbaum et al., 2020). Coprimary endpoints 
(change in WOMAC Pain, WOMAC Physical Function and PGA- OA at Week 24) are adjusted for multiplicity. All other p- values are unadjusted: 
in line with the predefined gatekeeping strategy, hypothesis testing of the three key secondary endpoints could not be performed in addition to 
endpoints not defined as coprimary and key secondary endpoints. Pain, Physical Function and Stiffness subscales of the WOMAC questionnaire 
assessed index joint symptoms within the last 48 hr on 11- point numeric rating scales (0 = no pain/difficulty/stiffness, 10 = extreme pain/difficulty/
stiffness). PGA- OA assessed on a 5- point Likert scale (1 = very good, 5 = very poor) in response to the question: “Considering all the ways your 
osteoarthritis in your hip/knee affects you, how are you doing today?” ANCOVA with multiple imputation for missing data, including model terms 
for baseline score, baseline average daily index joint pain score, index joint, highest KL grade and treatment group, with study site as a random 
effect. Baseline scores (mean ± SD) for placebo (n = 281), tanezumab 2.5 mg (n = 282) and tanezumab 5 mg (n = 284) groups, respectively, 
were: 6.59 ± 0.94, 6.70 ± 0.94 and 6.60 ± 0.89 for WOMAC Pain; 6.67 ± 0.87, 6.77 ± 0.87 and 6.76 ± 0.88 for WOMAC Physical Function; 
6.46 ± 1.43, 6.44 ± 1.59 and 6.44 ± 1.53 for WOMAC Stiffness; and 3.55 ± 0.62, 3.61 ± 0.62 and 3.56 ± 0.63 for PGA- OA. ANCOVA, analysis 
of covariance; CI, confidence interval; KL, Kellgren- Lawrence; LS, least squares; PGA- OA, patient's global assessment of osteoarthritis; SD, 
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for WOMAC Pain (unadjusted p = .0008, Figure 3b) but this 
was not the case for Physical Function (unadjusted p = .1031, 
Figure  4b) score. Findings for the tanezumab 5  mg group 
were generally comparable to the tanezumab 2.5 mg group 
at Week 2 in terms of WOMAC Pain (Figure  3), Physical 
Function (Figure  4), and OMERACT- OARSI (Figure  5) 
responders.
3.3 | Maintenance of efficacy
In the total population, improvements in pain and function 
were maintained through the 24- week treatment period. 
Reductions from baseline in average daily index joint pain 
score (LS mean) were greater for each tanezumab group com-
pared with the placebo group at all weekly time points through 
Week 24 (unadjusted p ≤ .05), with the exception of the tan-
ezumab 2.5 mg group at Week 24 (Figure 1b). Reductions 
from baseline in WOMAC Pain, Physical Function and 
PGA- OA scores (LS mean) were greater for each tanezumab 
group compared with the placebo group at all time points 
through Week 16 (unadjusted p ≤  .05, Figure 2) and were 
statistically significant at Week 24 (Berenbaum et al., 2020) 
(p ≤ .05) with the exception of PGA- OA in the tanezumab 
2.5  mg group. Effect sizes for WOMAC Pain at Week 24 
were 0.24 (tanezumab 2.5 mg) and 0.32 (tanezumab 5 mg) 
(Berenbaum et al., 2020) (Table S3). Greater reductions from 
baseline in WOMAC Stiffness score (LS mean) were also 
seen for each tanezumab group compared with the placebo 
group at all time points through Week 24 (Figure 2c). After 
the Week 2 measurement, further improvements from base-
line in pain and function were evident at Week 4 (Figures 1b 
and 2).
Rescue medication use (days per week) was lower for both 
tanezumab groups compared with the placebo group at Week 
4 through Week 12 (LS mean, unadjusted p ≤ .05), but not 
at Week 16 or 24 (Table  2). There were no differences in 
the amount of rescue medication used per week (mg) by ei-
ther tanezumab group compared with the placebo group from 
Week 4 through Week 24 (Table S4).
At all time points through Week 24, a higher proportion 
of patients in the tanezumab 2.5 mg group than in the pla-
cebo group achieved ≥30% reductions in WOMAC Pain 
(Figure 3a) and Physical Function (Figure 4a) score and met 
the criteria for OMERACT- OARSI response (Figure 5) (un-
adjusted p ≤ .05). The proportion of patients achieving ≥50% 
reduction in WOMAC Pain (Figure 3b) or Physical Function 
(Figure  4b) score was greater for the tanezumab 2.5  mg 
group versus placebo at Week 4 through Week 24 (unad-
justed p ≤ .05). Findings for the tanezumab 5 mg group were 






Week 2 LS mean (95% CI) 3.17 (2.69, 3.74) 2.12 (1.78, 2.52) 2.39 (2.02, 2.83)
LS mean ratio (95% CI) versus placebo 0.67 (0.54, 0.82) 0.75 (0.61, 0.92)
Unadjusted p- value 0.0001 0.0067
Week 4 LS mean (95% CI) 2.82 (2.32, 3.41) 1.81 (1.49, 2.20) 2.07 (1.70, 2.52)
LS mean ratio (95% CI) versus placebo 0.64 (0.51, 0.82) 0.74 (0.58, 0.93)
Unadjusted p- value 0.0003 0.0112
Week 8 LS mean (95% CI) 2.54 (2.09, 3.10) 1.83 (1.50, 2.24) 1.92 (1.57, 2.34)
LS mean ratio (95% CI) versus placebo 0.72 (0.56, 0.92) 0.75 (0.59, 0.96)
Unadjusted p- value 0.0093 0.0237
Week 12 LS mean (95% CI) 2.29 (1.83, 2.88) 1.70 (1.35, 2.14) 1.72 (1.37, 2.17)
LS mean ratio (95% CI) versus placebo 0.74 (0.56, 0.98) 0.75 (0.57, 1.00)
Unadjusted p- value 0.0374 0.0468
Week 16 LS mean (95% CI) 2.11 (1.69, 2.63) 1.64 (1.31, 2.06) 1.70 (1.37, 2.13)
LS mean ratio (95% CI) versus placebo 0.78 (0.59, 1.03) 0.81 (0.61, 1.06)
Unadjusted p- value 0.0751 0.1305
Week 24 LS mean (95% CI) 1.74 (1.36, 2.23) 1.49 (1.17, 1.89) 1.43 (1.12, 1.83)
LS mean ratio (95% CI) versus placebo 0.85 (0.63, 1.16) 0.82 (0.61, 1.11)
Unadjusted p- value 0.3057 0.2056
Note: Last observation carried forward. Negative Binomial model terms included baseline WOMAC Pain score, baseline average daily index joint pain score, index 
joint, highest KL grade and treatment group.
Abbreviations: CI, confidence interval; KL, Kellgren- Lawrence; LS, least squares; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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generally comparable to the tanezumab 2.5 mg group through 
the treatment period in terms of WOMAC Pain (Figure  3), 
Physical Function (Figure  4) and OMERACT- OARSI 
(Figure 5) responders.
At Week 16 and Week 24, patient satisfaction based on the 
mPRTI was better for each tanezumab group compared with 
placebo (unadjusted p ≤ .05, Table S5).
From Week 24 to Week 32, pain and functional disabil-
ity gradually returned but did not increase above baseline. At 
Week 32, changes from baseline (mean ± SD, observed data) 
for placebo and tanezumab 2.5 mg and 5 mg groups, respec-
tively, were −2.19 ± 2.40, −2.07 ± 2.33, and −2.13 ± 2.40 
for average daily index joint pain score; −2.70  ±  2.06, 
−2.29 ± 1.95 and −2.26 ± 2.24 for WOMAC Pain score; and
−2.55 ± 1.98 −2.22 ± 1.92 and −2.24 ± 2.09 for WOMAC
Physical Function score. At Week 32, PGA- OA and WOMAC 
Stiffness scores also did not increase above baseline (data not
shown).
3.4 | Subgroup analyses based on KL 
grade of the index joint
For the KL4 subgroup, there was a greater improvement 
from baseline in WOMAC Pain and Physical Function 
scores (LS mean) for each tanezumab group compared 
with placebo at all time points from Week 2 through Week 
24 (unadjusted p ≤ .05). For the KL2/3 subgroup, the LS 
mean improvement from baseline in WOMAC Pain and 
Physical Function scores was greater for the tanezumab 
2.5 mg group (at Weeks 2, 4, and 12) and the tanezumab 
5 mg group (at Weeks 4, 8 and 12), compared with placebo 
(unadjusted p ≤ .05). In the tanezumab 2.5 mg group, the 
placebo- adjusted change from baseline in WOMAC Pain 
score (LS mean difference) at Week 24 was −0.84 for the 
KL4 subgroup and −0.19 for the KL2/3 subgroup, and im-
provements in WOMAC Physical Function were −1.01 
and −0.28, respectively (Table 3).
F I G U R E  3  Proportion of patients with (a) ≥30%, (b) ≥50%, (c) ≥70%, or (d) ≥90% reduction from baseline in WOMAC Pain score 
throughout the treatment period (total population). *Unadjusted p ≤ .05 versus placebo. The data for Week 24 have been previously published 
(Berenbaum et al., 2020). Two patients not evaluable for this outcome, one in each of the placebo and tanezumab 2.5 mg groups. Logistic 
regression with mixed baseline/last observation carried forward, with model terms for baseline score, baseline average daily index joint pain score, 
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F I G U R E  4  Proportion of patients with (a) ≥30%, (b) ≥50%, (c) ≥70%, or (d) ≥90% reduction from baseline in WOMAC Physical Function 
score throughout the treatment period (total population). *Unadjusted p ≤ .05 versus placebo. Two patients not evaluable for this outcome, one in 
each of the placebo and tanezumab 2.5 mg groups. Logistic regression with mixed baseline/last observation carried forward, with model terms for 
baseline score, baseline average daily index joint pain score, index joint, highest KL grade and treatment group. KL, Kellgren- Lawrence; WOMAC, 
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Placebo (n = 282) Tanezumab 2.5 mg (n = 283) Tanezumab 5 mg (n = 284)
F I G U R E  5  Patients meeting the criteria for OMERACT- OARSI response during the 24- week treatment period (total population). 
*Unadjusted p ≤ .05 versus placebo. Two patients not evaluable for this outcome, one in each of the placebo and tanezumab 2.5 mg groups. 
Logistic regression with mixed baseline/last observation carried forward, with model terms for baseline WOMAC Pain score, baseline average 
daily index joint pain score, index joint, highest KL grade and treatment group. KL, Kellgren- Lawrence; OMERACT- OARSI, Outcomes Measures 
in Rheumatology- Osteoarthritis Research Society International; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index
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3.5 | Subgroup of patients from Japan
The onset and maintenance of efficacy of tanezumab in the 
subgroup of patients from Japan was consistent with that 
of the total population, including LS mean reductions from 
baseline in WOMAC Pain, Physical Function and PGA- OA 
scores (the coprimary endpoints) at Week 24 (Table 1).
At Week 2, notably more patients in the tanezumab 2.5 mg 
(23.7%, 9/38) and 5 mg (29.4%, 10/34) groups than the pla-
cebo group (14.7%, 5/34) had ≥30% reduction in WOMAC 
Pain score; a similar pattern was seen for the ≥50% reduction 
in WOMAC Pain score criterion (tanezumab 2.5 mg [13.2%, 
5/38], tanezumab 5 mg [14.7%, 5/34], placebo [2.9%, 1/34]). 
At Week 24, ≥30% reduction in WOMAC Pain score was 
achieved by 63.2% (24/38) of patients in the tanezumab 
2.5  mg group, 55.9% (19/34) of patients in the tanezumab 
5  mg group and 32.4% (11/34) of patients in the placebo 
group; a similar pattern was seen for the ≥50% reduction in 
WOMAC Pain score criterion (tanezumab 2.5  mg [36.8%, 
14/38], tanezumab 5  mg [44.1%, 15/34], placebo [14.7%, 
5/34]). However, the small sample size of the subgroup of 
patients from Japan means that interpretation of those find-
ings should be treated cautiously.
3.6 | Safety
Safety data for the total population are reported in full else-
where (Berenbaum et al., 2020). In the subgroup of patients 
from Japan, safety outcomes were not markedly different 
from those of the total population during the double- blind 
treatment period, although the sample size was small.
4 |  DISCUSSION
This exploratory analysis found that in patients with 
moderate- to- severe OA for whom standard analgesics were 
inadequate or could not be taken, the onset of efficacy of sub-
cutaneous tanezumab was within the first week, and efficacy 
was maintained through the 24- week treatment period.
The early and sustained efficacy of tanezumab seen in the 
current study in patients enrolled in Europe and Japan is sup-
ported by a previous study in North America with primary 
endpoints at Week 16 (Schnitzer et al., 2020). Both studies 
showed greater improvement from baseline in WOMAC Pain, 
Physical Function and PGA- OA scores (LS mean) at Week 
16 for tanezumab compared with placebo. For the tanezumab 
2.5 mg group, the mean baseline WOMAC Pain score in the 
current study (6.7) was lower than in the North American 
study (7.1) (Schnitzer et al., 2020), which may account for the 
smaller magnitude of the changes from baseline in the current 
study across all three outcomes at Week 16 (Figure  2 and 
Table S6). Efficacy was largely similar for tanezumab 2.5 mg 
and 5 mg in the current study, and the small differences are 
not considered clinically meaningful. Only limited additional 
efficacy was seen previously with dose titration from 2.5 mg 
to 5 mg (Schnitzer et al., 2020), but more joint safety findings 
have been observed with tanezumab 5 mg than tanezumab 
2.5 mg (Berenbaum et al., 2020).
The improvements in pain seen in the current study are 
clinically meaningful. The effect sizes for average daily index 
joint pain at Week 1, WOMAC Pain at Week 2, as well as 
WOMAC Pain at Week 24 (Berenbaum et al., 2020) are all 
above the suggested lower threshold for meaningfulness (0.2) 
(Cohen, 1988) for both tanezumab groups (Table S3). Both 
tanezumab groups also used less rescue medication (LS mean 
days per week) compared with the placebo group through 
Week 12 in the current study.
The problems associated with evaluating effectiveness 
based on mean improvements have been discussed, including 
negligible mean benefits that reach statistical significance if 
the study is sufficiently powered, and the influence of indi-
viduals with a very large improvement on the overall mean 
despite others experiencing worsening pain or little improve-
ment (Dworkin et al., 2008). Furthermore, since each patient 
experiences pain differently, assessing individual responses 
to treatment (Dworkin et  al.,  2008) is arguably more rele-
vant. Within- patient improvements in WOMAC Pain score 
of 30% or more relative to baseline are often reported to 
be moderately clinically important (Dworkin et  al.,  2008; 
Farrar et  al., 2001). In the current study, 46.8% of patients 
treated with tanezumab 2.5  mg (compared with 33.5% for 
placebo) experienced a moderate (≥30%) clinically import-
ant (Dworkin et al., 2008) reduction in WOMAC Pain score 
at Week 2, and 27.7% of patients treated with tanezumab 
2.5 mg (compared with 16.7% for placebo) had a substantial 
(≥50%) clinically important (Dworkin et al., 2008) reduction 
in WOMAC Pain; this was sustained through the 24- week 
study. It should be noted that although a 30% change from 
baseline in WOMAC Pain score is widely used as a threshold 
for meaningful relief, a 10%– 20% improvement is noticeable 
to some patients (Dworkin et al., 2008).
These clinically meaningful improvements are sup-
ported by the other outcomes. Although clinically relevant 
improvements in WOMAC Physical Function score remain 
to be elucidated, applying the same cut- off criteria (≥30% 
improvement) as for pain demonstrates greater improvement 
in function for tanezumab compared with placebo through-
out the study. More patients in both tanezumab groups com-
pared with placebo met the criteria for the clinically relevant 
OMERACT- OARSI response (Pham et al., 2003, 2004) at all 
time points through Week 24 (Figure  5). Satisfaction with 
treatment as reported by patients was greater at Weeks 16 and 
24 for patients treated with tanezumab compared with those 
treated with placebo.
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The subgroup analysis based on KL grade of the index 
joint indicated that subcutaneous tanezumab was effective 
in patients with the most radiographically severe OA (KL4). 
Interestingly, the magnitude of the placebo- adjusted changes 
from baseline (LS mean) was greater for the KL4 subgroup 
compared with the KL2/3 subgroup. The tanezumab re-
sponse was similar but the placebo response was greater for 
the KL2/3 subgroup versus the KL4 subgroup (Table  3). 
There are few data available for comparison that examine the 
efficacy of any analgesic specifically in patients with radio-
graphically severe OA, and considering the often inconsistent 
association between pain and radiographic findings (Kinds 
et al., 2011), those findings with tanezumab warrant future 
investigation.
The efficacy of tanezumab in the small subgroup of pa-
tients from Japan was consistent with the total population. 
At Week 24, the change from baseline in WOMAC Pain and 
Physical Function and PGA- OA scores (LS mean) in the pla-
cebo group as well as the tanezumab groups was smaller in 
the Japanese subgroup compared with the total population 
(Table  1); however, the magnitude of the placebo- adjusted 
changes were consistently greater in the subgroup of patients 
from Japan.
The limitations of this study have been discussed previ-
ously (Berenbaum et al.,  2020). The post hoc nature of the 
subgroup analyses based on KL grade of the index joint, and 
the small sample size of the subgroup of patients from Japan, 
means that interpretation of those findings should be treated 
cautiously.
5 |  CONCLUSIONS
This exploratory analysis found that in patients with 
moderate- to- severe OA for whom standard analgesics were 
not effective or could not be taken, the onset of efficacy of 
subcutaneous tanezumab was within the first week, and ef-
ficacy was maintained through the 24- week treatment pe-
riod. Although the effect sizes were modest, more patients 
treated with tanezumab than placebo had a clinically impor-
tant within- patient reduction in WOMAC Pain, correspond-
ing improvement in WOMAC Physical Function, and met the 
criteria for OMERACT- OARSI response, at all time points 
during the 24- week treatment period. The tanezumab groups 
also reported more patient satisfaction compared with pla-
cebo. Tanezumab was effective in those patients with the 
most radiologically severe OA, for whom the placebo re-
sponse was less pronounced.
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